Exact sciences corporation stock.

10-Apr-2023 ... MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic ...Dec 1, 2023 · Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ... Exact Sciences Corporation (NasdaqCM:EXAS) acquired Sampleminded, Inc. for $7.6 million on August 1, 2017. Under the terms, Exact Sciences paid $3.2 million in cash and issued 0.09 million restricted stock units.Tucson, Ariz. (February 1, 2023) - The PGA TOUR Champions, the Tucson Conquistadores, the First Tee Tucson, and Exact Sciences, the maker of Cologuard ®, announced today that the Madison, Wisconsin-based company will now be the presenting sponsor of the Cologuard Classic.The announcement also extends Cologuard's title …

Advertisement Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 65.27 +0.68 (+1.05%) At close: 04:00PM EDT 65.50 +0.23 (+0.35%) After...Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ...

EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. EXAS Stock Performance. USD USD; Previous close: 64.97: 64.97: Day range: 64.965 - 67.9864.965 - 67.98Year range:

MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's …Exact Sciences Corporation. 01 Aug, 2023, 16:05 ET. Reports record results, generates positive free cash flow, raises full-year guidance. Second-quarter 2023 highlights. Total second quarter ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more. Exact Sciences is best known for Cologuard, a non-invasive colorectal cancer screening test that uses stool samples to look for cancerous cells. The company also has tests to detect liver cancer. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and ...

From hereditary cancer testing and earlier cancer screenings to treatment guidance and therapy selection, we aim to offer a comprehensive suite of tests that ...

Jul 10, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...

From hereditary cancer testing and earlier cancer screenings to treatment guidance and therapy selection, we aim to offer a comprehensive suite of tests that ...Sep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link. Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov. 01.Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.© Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719 Powered By Q4 Inc. 5.111.2.6 5.111.2.6Nov 13, 2023 · Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Analysts expect adjusted earnings to reach $-1.363 per share for the current fiscal year. Exact Sciences Corp does not currently pay a dividend.

Advertisement Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 65.27 +0.68 (+1.05%) At close: 04:00PM EDT 65.50 +0.23 (+0.35%) After... Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Exact Sciences ( NASDAQ: EXAS) said that its next-generation Cologuard screening test for colon cancer showed better cancer specificity and sensitivity compared to the currently marketed test ...Company profile page for Exact Sciences Corp including stock price, company news, press releases, executives, board members, and contact informationFind the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Company profile page for Exact Sciences Corp including stock price, company news, press releases, executives, board members, and contact informationGlobally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...

26-Apr-2022 ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...

EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. EXAS Stock Performance. USD USD; Previous close: 64: 64: Day range: 62.76 - 67.0362.76 - 67.03Year range: 43 - 100Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.Find the latest Exact Sciences Corporation (EXK.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Corporate Impact and Community Relations. Our Collaborations. Contact Us. Newsroom. News & Stories. ... Stock Information. ... CANCER IS DETECTED TOO LATE. Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful ...In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ...06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...Mar 2, 2023 · In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ... Oncotype DX ® Test Recognized as the 'Preferred' and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer. Update based on first results from the independent RxPONDER study presented at the 2020 San Antonio Breast Cancer Symposium 1. Madison, Wis., March 31, 2021 - Exact Sciences today …

Nov 17, 2023 · Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and commercializes diagnostic tests for cancer and other diseases. See real-time data, market cap, key data and news of EXAS on Nasdaq.

Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA …

Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqDec 1, 2023 · 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.Sep 30, 2023 · Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ... MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ...EXACT Sciences Corporation (EXAS) NASDAQ Currency in USD Disclaimer Add to Watchlist 63.77 +0.32 (+0.50%) Real-time Data 14:22:38 Fair Value Unlock Value Day's …Sep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link. But EXAS stock toppled 4.3% on Wednesday after the company announced the Blue-C results. The tumble is likely related to the new product's minimal improvement in finding precancerous polyps. Those ...MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.

Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com. About Exact Sciences Corp.09-Oct-2023 ... MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests ...11-Feb-2020 ... Exact Sciences Announces Fourth-Quarter 2019 Results ; Net income (loss) per share—basic. $. 0.56 ; Net income (loss) per share—diluted. $. 0.54.The Exact Sciences Corp (NASDAQ: EXAS) stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days. Most of that value climb came yesterday, with the ...Instagram:https://instagram. dividend oil stocksus based prop firmsstoke adobeauto parts stocks 06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ... alarm stockeva stock forecast In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ... jim crammer Purchasing Exact Sciences Corporation (EXAS) share from India can be done by: Directly: By opening an international trading account with Angel One.The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Exact Sciences Corporation (EXAS) by making …Exact Sciences Corp. historical stock charts and prices, analyst ratings, financials, and today's real-time EXAS stock price.Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to …